Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TZP-101 in Severe Diabetic Gastroparesis
2007-003279-38Phase 2Terminated
- Sponsor
- Tranzyme Pharma
- Start
- Jul 2007
- Modality
- Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetic gastroparesis comparing TZP-101 IV infusion arm with Placebo IV infusion arm (2 arms). Primary endpoint: Change from baseline in mean GCSI post-prandial fullness/early satiety subscale score. Started Jul 2007; status: terminated.
02
Drugs
ulimorelin
03
Conditions
diabetic gastroparesis
Beyond the preview
Go deeper on 2007-003279-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003279-38.